Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.

Xia H, Min Y, Wang Y, Gao S, Wang H, Yan F, Liu R, Wang J, Gu X, Bo T

Radiology1 Aug 2025Cited by 4 (Europe PMC)

PMID40828048DOI10.1148/radiol.243780PepBankPUB-40828048

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet-fed mice, mazdutide reduced MRI liver fat fraction (PDFF) from baseline more than semaglutide after 4 weeks.
In plain wordsIn mice fed a high-fat diet, mazdutide reduced liver fat more than semaglutide after 4 weeks.
Peptide
Mazdutide
Outcome
DecreaseHepatic fat (PDFF) reduction at 4 weeks
Study
mousen: not reported in source
High-fat diet-induced mouse model
Comparator
Semaglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
Median PDFF change
−5.59%
mazdutide, 4 weeks
Median PDFF change
−3.3%
semaglutide, 4 weeks
Source sentences
Summary
Results After 4 weeks of treatment, mice treated with the dual agonist showed a greater reduction in PDFF from baseline values compared with mice treated with the monoagonist (median change, -5.59% [IQR, -6.80, -3.84] vs -3.30% [IQR, -3.80, -2.82]; P = .02).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804801
02AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet-fed mice, the reduction in liver fat fraction (PDFF) after 1 week did not differ between mazdutide and semaglutide.
In plain wordsIn mice fed a high-fat diet, liver fat fell similarly with mazdutide and semaglutide after 1 week.
Peptide
Mazdutide
Outcome
No significant changeHepatic fat (PDFF) reduction at 1 week
Study
mousen: not reported in source
High-fat diet-induced mouse model
Comparator
Semaglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
Median PDFF change
−2.15%
mazdutide, 1 week
Median PDFF change
−1.24%
semaglutide, 1 week
Source sentences
Summary
At 1 week after treatment, there was no evidence of a difference in PDFF reduction from baseline between the two groups (median change, -2.15% [IQR, -5.10, -1.69] vs -1.24% [IQR, -2.95, -0.78]; P = .19).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804802
03AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet-fed mice, the decrease in hepatic iron signal (R2*) at 1 week did not differ significantly between mazdutide and semaglutide.
In plain wordsIn mice fed a high-fat diet, liver iron signal fell similarly with mazdutide and semaglutide after 1 week.
Peptide
Mazdutide
Outcome
No significant changeHepatic iron (R2*) decrease at 1 week
Study
mousen: not reported in source
High-fat diet-induced mouse model
Comparator
Semaglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
Median R2* change
−53.86 Hz
mazdutide, 1 week
Median R2* change
−46.17 Hz
semaglutide, 1 week
Source sentences
Summary
Decreases in R2* values from baseline were also not significantly different between the groups at 1 week (median change, -53.86 Hz [IQR, -76.79, -43.19] vs -46.17 Hz [IQR, -68.01, -35.04]; P = .50)
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804803
04AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet-fed mice, the decrease in hepatic iron signal (R2*) at 4 weeks did not differ significantly between mazdutide and semaglutide.
In plain wordsIn mice fed a high-fat diet, liver iron signal fell similarly with mazdutide and semaglutide after 4 weeks.
Peptide
Mazdutide
Outcome
No significant changeHepatic iron (R2*) decrease at 4 weeks
Study
mousen: not reported in source
High-fat diet-induced mouse model
Comparator
Semaglutide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
Median R2* change
−67 Hz
mazdutide, 4 weeks
Median R2* change
−57.18 Hz
semaglutide, 4 weeks
Source sentences
Summary
and 4 weeks (median change, -67.00 Hz [IQR, -79.33, -44.66] vs -57.18 Hz [IQR -78.51, -12.85]; P = .41) after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Decreases in R2* values from baseline were also not significantly different between the groups
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804804
05AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet mice, semaglutide reduced liver PDFF from baseline at 4 weeks (median -3.30%), a smaller reduction than with mazdutide (median -5.59%, P = .02).
In plain wordsIn mice on a high-fat diet, semaglutide reduced liver fat, but less than mazdutide did after 4 weeks.
Peptide
Semaglutide
Outcome
DecreaseLiver fat (PDFF) reduction at week 4
Study
mousen: not reported in source
high-fat diet-induced obese mice
Comparator
Mazdutide (GLP-1R/GCGR dual agonist)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
PDFF change
−3.3%
semaglutide, 4 weeks
Source sentences
Summary
Results After 4 weeks of treatment, mice treated with the dual agonist showed a greater reduction in PDFF from baseline values compared with mice treated with the monoagonist (median change, -5.59% [IQR, -6.80, -3.84] vs -3.30% [IQR, -3.80, -2.82]; P = .02).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804808
06AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet mice, semaglutide reduced liver PDFF from baseline at 1 week (median -1.24%), with no evidence of a difference from mazdutide (-2.15%, P = .19).
In plain wordsIn mice on a high-fat diet, semaglutide reduced liver fat after 1 week, with no clear difference from mazdutide.
Peptide
Semaglutide
Outcome
DecreaseLiver fat (PDFF) reduction at week 1
Study
mousen: not reported in source
high-fat diet-induced obese mice
Comparator
Mazdutide (GLP-1R/GCGR dual agonist)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 1 weekAs given in this study (mouse).
Measurements
PDFF change
−1.24%
semaglutide, 1 week
Source sentences
Summary
At 1 week after treatment, there was no evidence of a difference in PDFF reduction from baseline between the two groups (median change, -2.15% [IQR, -5.10, -1.69] vs -1.24% [IQR, -2.95, -0.78]; P = .19).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804809
07AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet mice, semaglutide decreased liver R2* (iron content) from baseline at 1 week (median -46.17 Hz), not significantly different from mazdutide (P = .50).
In plain wordsIn mice on a high-fat diet, semaglutide lowered a liver iron marker after 1 week, with no clear difference from mazdutide.
Peptide
Semaglutide
Outcome
DecreaseLiver iron (R2*) change at week 1
Study
mousen: not reported in source
high-fat diet-induced obese mice
Comparator
Mazdutide (GLP-1R/GCGR dual agonist)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 1 weekAs given in this study (mouse).
Measurements
R2* change
−46.17 Hz
semaglutide, 1 week
Source sentences
Summary
Decreases in R2* values from baseline were also not significantly different between the groups at 1 week (median change, -53.86 Hz [IQR, -76.79, -43.19] vs -46.17 Hz [IQR, -68.01, -35.04]; P = .50) and 4 weeks (median change, -67.00 Hz [IQR, -79.33, -44.66] vs -57.18 Hz [IQR -78.51, -12.85];…
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804810
08AnimalAnimal study (in vivo)Efficacy outcome
In high-fat diet mice, semaglutide decreased liver R2* (iron content) from baseline at 4 weeks (median -57.18 Hz), not significantly different from mazdutide (P = .41).
In plain wordsIn mice on a high-fat diet, semaglutide lowered a liver iron marker after 4 weeks, with no clear difference from mazdutide.
Peptide
Semaglutide
Outcome
DecreaseLiver iron (R2*) change at week 4
Study
mousen: not reported in source
high-fat diet-induced obese mice
Comparator
Mazdutide (GLP-1R/GCGR dual agonist)
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (mouse).
Measurements
R2* change
−57.18 Hz
semaglutide, 4 weeks
Source sentences
Summary
Decreases in R2* values from baseline were also not significantly different between the groups at 1 week (median change, -53.86 Hz [IQR, -76.79, -43.19] vs -46.17 Hz [IQR, -68.01, -35.04]; P = .50) and 4 weeks (median change, -67.00 Hz [IQR, -79.33, -44.66] vs -57.18 Hz [IQR -78.51, -12.85];…
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
Report a problemFND-4082804811

Studies that did not test the peptide alone3

In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Mazdutide.

09AnimalNot a test of Mazdutide aloneAnimal study (in vivo)Other
In mice in the high-fat diet MRI study, liver PDFF correlated positively with hepatic triglyceride levels.
In plain wordsIn mice, higher MRI liver fat readings went with higher liver triglyceride levels measured in tissue.
Peptide
Mazdutide
Outcome
Not applicableCorrelation of PDFF with hepatic triglycerides
Study
mousen: not reported in source
High-fat diet-induced mouse model
Outcome group
Liver fat and liver function · Liver
Measurements
Pearson/Spearman r
0.82 r
PDFF vs hepatic triglycerides
Source sentences
Summary
Liver PDFF was positively correlated with hepatic triglyceride levels (r = 0.82; P < .001) and histologic steatosis scores (r = 0.81; P < .001), as well as R2* values (r = 0.69; P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4082804805
10AnimalNot a test of Mazdutide aloneAnimal study (in vivo)Other
In mice in the high-fat diet MRI study, liver PDFF correlated positively with histologic steatosis scores.
In plain wordsIn mice, higher MRI liver fat readings went with higher steatosis scores seen in tissue slides.
Peptide
Mazdutide
Outcome
Not applicableCorrelation of PDFF with histologic steatosis
Study
mousen: not reported in source
High-fat diet-induced mouse model
Outcome group
Liver fat and liver function · Liver
Measurements
Pearson/Spearman r
0.81 r
PDFF vs steatosis score
Source sentences
Summary
Liver PDFF was positively correlated with hepatic triglyceride levels (r = 0.82; P < .001) and histologic steatosis scores (r = 0.81; P < .001), as well as R2* values (r = 0.69; P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4082804806
11AnimalNot a test of Mazdutide aloneAnimal study (in vivo)Other
In mice in the high-fat diet MRI study, liver PDFF correlated positively with R2* values.
In plain wordsIn mice, higher MRI liver fat readings went with higher MRI liver iron signal values.
Peptide
Mazdutide
Outcome
Not applicableCorrelation of PDFF with R2*
Study
mousen: not reported in source
High-fat diet-induced mouse model
Outcome group
Liver fat and liver function · Liver
Measurements
Pearson/Spearman r
0.69 r
PDFF vs R2*
Source sentences
Summary
Liver PDFF was positively correlated with hepatic triglyceride levels (r = 0.82; P < .001) and histologic steatosis scores (r = 0.81; P < .001), as well as R2* values (r = 0.69; P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-4082804807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.

Summary

Results from this study11

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

MeSH terms